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Abstract: By mimicking the native extracellular matrix, electrospun nanofibrous   scaffolds 
(ENSs) can provide both chemical and physical cues to modulate cell adherence and   differentiation 
and to promote tissue regeneration while retaining bioresorbable and biocompatible properties. 
In this study, ENSs were developed to deliver multiple biomolecules by loading them into 
the core-sheath structure and/or by conjugating them to the nanofiber surfaces. In this work, 
poly(L-lactide)-poly(ethylene glycol)-NH2 and poly(L-lactide) were emulsion electrospun 
into nanofibers with a core-sheath structure. A model drug, tetracycline hydrochloride, was 
loaded within the nanofibers. Amino and carboxyl reactive groups were then activated on 
the fiber surfaces using saturated water vapor exposure and base hydrolysis, respectively. These 
reactive groups allowed the surface of the ENS to be functionalized with two other bioactive 
molecules, fluorescein isothiocyanate- and rhodamine-labeled bovine serum albumins, which 
were used as model proteins. The ENSs were shown to retain their antimicrobial capacity 
after two functionalization reactions, indicating that multifunctional nanofibers can potentially 
be developed into functional wound dressings or periodontal membranes or used in more 
  complicated tissue systems where multiple growth factors and anti-infection precautions are 
critical for the successful implantation and regeneration of tissues.
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Introduction
One promising strategy used in tissue regeneration involves forming bioresorbable 
and biocompatible materials into scaffolds in a way that mimics or replicates native 
tissues. Many strategies have been proposed for engineering biomimetic scaffolds, 
such as freeze-drying,1 solvent-free techniques,2 and electrospinning methods.3 
  Electrospun nanofibrous scaffolds (ENSs) have recently been gaining interest in the 
tissue   engineering field because of their many advantages.
ENSs provide temporary spaces with a tunable porosity in which cells can exchange 
metabolites and nutrients with their environment so as to maintain   cellular functionality 
and to aid in the reconstruction of tissues while also maintaining   tailored mechanical 
properties to protect the wound bed from collapse and to avoid mechanical mismatch 
between scaffolds and host tissues.4 By replicating host tissue matrices, ENSs can 
regulate stem cell differentiation and promote cell ingrowth.5 More importantly, 
ENSs can be fabricated as drug carriers to release therapeutic agents into wounds 
in a   controlled manner instead of direct injections of drugs that are expensive and 
inefficient. For example, anticancer drugs (such as doxorubicin hydrochloride6 
and paclitaxel7) and antibacterial agents (such as cefazolin,8 cefoxitin sodium,9 and 
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  tetracycline hydrochloride [TCH])10 have been loaded into 
nanofibers. These drugs can be randomly distributed in 
nanofibers11 or can be entrapped in the core of the fibers.6,10 
Co-axial and emulsion electrospinning processes produce 
nanofibers with core-sheath structures that provide a more 
sustained release of drugs.6
One of the focuses of tissue engineering is the manipulation 
and regulation of stem cell fate within a hierarchical 
structure into which cells can attach, spread, differentiate, 
and proliferate.12 Nanofibers can be functionalized with a 
variety of regulators (such as growth factors, morphogens, 
antibiotics, or functional groups) to modify the local cell 
environment niche and to ultimately change cell fate.13–18 Kim 
and Park19 fabricated lysozyme-functionalized nanofibers 
made of a polycaprolactone and poly(lactide-co-glycolide)-
b-poly(ethylene glycol)-NH2 diblock copolymer. Patel 
et al18,20 fabricated heparin- and basic fibroblast growth 
factor-functionalized poly(L-lactide) (PLLA) nanofibers by 
using di-NH2-poly(ethylene glycol) as a linker molecule. 
The results showed that the laminin-modified nanofiber mats 
induced neurite outgrowth and promoted cell migration.18,20 
Interactions between the fiber surfaces and proteins affect the 
success of scaffold implantation by modulating cell adhesion 
and immigration, potentially triggering a cascade of foreign 
body responses and even promoting bacteria adhesion. 
Poly(ethylene glycol) (PEG) has been demonstrated to 
prevent nonspecific protein adsorption and to increase 
circulation time.21,22
Despite the large amount of research on functionalized 
nanofibers, there has been little work on the development 
of nanofibers with more than two incorporated bioactive 
molecules. However, multifunctional nanofibers are desirable 
for applications in wound healing, as they could protect 
the wound from infection and promote tissue reconstruction. 
Therefore, in this study, multifunctional PLLA/PLLA-b-PEG 
nanofibers were developed. A model antibiotic, TCH, was 
loaded into the PLLA/PLLA-b-PEG nanofibrous scaffold 
via emulsion electrospinning.23,24 The surfaces of the drug-
loaded nanofibers were then modified to allow covalent 
conjugation of bioactive molecules. Two fluorescently tagged 
bovine serum albumins (BSAs) were used as model proteins 
for immobilization. Using microorganism susceptibility 
tests, confocal microscopy, and Fourier transform infrared 
attenuated total reflectance (FTIR-ATR) analysis, this study 
showed that multiple proteins were successfully conjugated 
to the nanofibrous scaffolds. Finally, the conjugation of 
peptide Arg-Gly-Asp-Ser (RGDS) and platelet-derived 
growth factor (PDGF)-BB on scaffolds promoted the growth 
of human dermal fibroblasts (HDFs). The strategy has 
potential applications in tissue engineering and regenerative 
medicine.
Materials and methods
Materials
L-lactide and PLLA (molecular weight [MW] 220 × 103 g/mol) 
were obtained from Purac USA (Lincolnshire, IL). NaOH 
($98%), benzyltriethylammonium chloride (BTAC) (98%), 
BSA ($96%), 2-mercaptoethanol, fluorescein   isothiocyanate 
(FITC)-conjugated BSA, rhodamine   isothiocyanate, and 
peptide RGDS were from Sigma-Aldrich (Oakville, ON). 
Recombinant human PDGF-BB, BODIPY® FL Phallacidin 
and ToPro®-3 were purchased from Invitrogen (Carlsbad, CA). 
HDF was from ATCC (Manassas, VA). 1-Ethyl-3-(3-dimethyl 
aminopropyl) carbodiimide hydrochloride (EDC), sulfo-
N-hydroxysuccinimide (sulfo-NHS), ethylene glycol-bis 
(succinimidyl succinate) (EGS), TCH ($95%), dimethyl 
sulfoxide (DMSO), and snake skin pleated dialysis tubing 
(MW cutoff = 7000) were from Fisher Scientific (Ottawa, ON). 
PEG (MW = 5000 Da, polydispersity index [PDI] = 1.03) 
with functional end groups (HO-PEG5000-NH2) was from 
JenKem Technology USA, Inc (Allen, TX). All reagents were 
used without further purification. To prepare rhodamine-
BSA, rhodamine isothiocyanate was first dissolved in DMSO 
at a concentration of 5 µg/µL. Rhodamine solution (50 µL) 
was slowly added to 1 µL of BSA solution (1.5 µg/µL). 
After overnight reaction at room temperature, the solution 
was purified in a dialysis bag (7000 MW cutoff) against 
phosphate-buffered saline (PBS) (pH 7.4) to remove the 
residual rhodamine.
For the preparation of PLLA-b-PEG-NH2, HO-PEG-
NH2 was dissolved in a mixture of aqueous NaOH and 
  tetrahydrofuran, and di-tert-butyl dicarbonate (Boc2O) 
was added to obtain HO-PEG-NBoc. The diblock copo-
lymer PLLA-b-PEG-NBoc was prepared by ring-opening 
  polymerization of L-lactide in the presence of HO-PEG-NBoc 
as a macro-initiator and diethylzinc as a catalyst. PLLA-b-
PEG-NBoc was then dissolved in a solvent mixture of CH2Cl2 
and trifluoroacetic acid (TFA) at 0°C for 2 hours. TFA and 
CH2Cl2 were removed in a vacuum, and the remaining solid 
was dissolved in a mixture of chloroform and triethylamine. 
The final PLLA-b-PEG-NH2 product was precipitated out. 
Gel permeation chromatography revealed that the block 
copolymer had an Mn (number average molecular weight) 
of 20 kDa and a PDI of 1.3, indicating a narrow   molecular 
weight distribution. The nuclear magnetic resonance 
  spectrum is shown in Supplementary Figure 1.
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Electrospun PLLA/PLLA-PEG-NH2 
nanofibrous scaffolds
The polymers PLLA and PLLA-PEG-NH2 at 70:30 w/w, and 
a surfactant, BTAC (5% w/w to polymers), were dissolved in 
chloroform and electrospun at a concentration of 7.5% w/w 
at room temperature, at a voltage of 22 kV , at a flow rate of 
7 mL/h, and with a distance of 12 cm between the needle tip 
and the collector. The morphology of the electrospun nanofi-
bers was examined using scanning electron microscopy (SEM) 
(Cambridge Stereoscan 120, Cambridge, UK) with accelerat-
ing voltage 20 kV . Samples were mounted on metal stubs using 
a double-sided adhesive tape and vacuum-coated with a gold 
layer prior to examination. To determine the average fiber 
diameter for each sample, ten fibers from each sample were 
randomly selected in the SEM images, and fiber diameters 
were measured at six different points on each fiber by ImageJ 
(National Institutes of Health, Bethesda, MD) software.
Fabrication of TCH-loaded nanofibers  
by emulsion electrospinning
TCH-loaded nanofibers were fabricated via emulsion 
electrospinning.23,24 Briefly, a 1 mL aqueous solution   containing 
3% w/w of TCH (with respect to the polymers) was emulsified 
in 20 mL of polymer solution containing 7.5% w/w PLLA/
PLLA-PEG-NH2 (with a blend ratio of 70:30 w/w) dissolved in 
chloroform. The emulsification took place in a homogenizer at 
7000 rpm for 20 minutes. During the process of emulsification, 
the emulsion was placed in an ice bath to minimize the 
evaporation of chloroform by the homogenizer. To obtain 
a stable and homogeneous water-in-oil (W/O) emulsion, 
5% w/w BTAC (with respect to the polymer) was added to the 
oily phase prior to emulsification as a surfactant to lower the 
surface tension of the polymer solution. The homogeneous W/O 
emulsion was then electrospun to yield TCH-loaded PLLA/
PLLA-b-PEG nanofibers.
Surface functionalization of electrospun 
nanofibers for the immobilization  
of proteins
Figure 1 shows the procedure for immobilizing FITC-BSA 
and rhodamine-BSA onto drug-loaded nanofibers. Briefly, 
the drug-loaded PLLA/PLLA-PEG-NH2 scaffolds were first 
treated with saturated water vapor for 15 minutes to expose 
the amino groups on the surface of the fibers. These amino 
Step 1
Step 2
Saturated 
water vapor  
FITC-BSA
Hydrolysis in 
NaOH  
Rhodamine 
BSA 
Figure 1 Functionalization procedure of PLLA/PLLA-PEG-NH2 nanofibers (brown). Step 1: Amino groups are activated by exposing nanofibers to saturated water vapor. 
Step 2: Carboxyl groups are activated by hydrolysis. Blue represents the loaded drug; red is rhodamine BSA; and green is FITC-BSA.
Abbreviations: BSA, bovine serum albumin; FITC, fluorescein isothiocyanate; PEG, poly(ethylene glycol); PLLA, poly(L-lactide).
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groups were conjugated to the carboxyl groups of rhodamine-
BSA via EGS. Each sample (5 mg) was immersed in 20 mL 
of DMSO containing 13.7 mg of EGS and gently agitated for 
1 hour at room temperature. The scaffolds were then removed 
and rinsed with distilled water three times and immersed 
in 20 mL of PBS containing 4.5 mg of rhodamine-BSA 
for 30 minutes to yield the functionalized scaffolds. The 
scaffolds were then washed three times with distilled water 
(dH2O) and treated with 0.01 M NaOH for 15 minutes to 
activate the carboxylic groups on the surface of the nanofibers 
as a result of surface hydrolysis.18 These carboxylic groups 
were then crosslinked with amine groups in FITC-BSA via 
EDC. The nanofiber mat was rinsed with dH2O and immersed 
in 20 mL of PBS solution containing 8 mg of EDC and 22 mg 
of sulfo-NHS, which was shaken gently and incubated for 
15 minutes. Then, 28 µL of 2-mercaptoethanol was added 
to the solution to quench the residual EDC. A volume of 
3 mL of 1.5 mg/mL FITC-BSA was added to the solution, 
and the reaction was allowed to proceed for 2 hours. The 
samples were rinsed three times with dH2O to remove the 
unreacted BSA from the surface of the nanofibers. SEM 
and confocal laser scanning microscopy (CLSM) (Olympus 
IX-70;   Olympus Corporation, Tokyo, Japan) were used to 
characterize the functionalized nanofibers. Supplementary 
Figure 2 shows the core-shell structure of drug-laden nano-
fibers after FITC-BSA conjugation only.
In vitro drug release
The profiles of TCH release from the TCH-loaded ENSs 
were monitored using an ultraviolet-visible (UV-Vis) 
  spectrometer at a wavelength of 366 nm. Each TCH-
loaded ENS (5 mg) was placed in a dialysis tube (cutoff 
MW = 7000) and incubated in 30 mL of PBS (Ph 7.4, 
0.01 M) at 37°C while the tube was gently shaken. At 
predetermined times, 6 mL of the incubation solution was 
removed, and 6 mL of fresh PBS, pH 7.4, was added to the 
solution. The TCH concentrations in the removed aliquots 
were then determined using a TCH standard curve. The 
cumulative release of TCH was   calculated and plotted as a 
function of the time of incubation.
Antibiotic susceptibility test
The samples tested for microorganism susceptibility are 
listed in Table 1. ENS samples 6.0 mm in diameter were 
punched from the fibrous assembly. Samples were func-
tionalized with TCH at 3%, with or without conjugated 
BSA. A   commercially available TCH-sensitive bacteria 
strain, Staphylococcus aureus ATCC (American Type 
Culture Collection, Seattle, WA) 25923 was used for this 
test. The samples were placed on agar plates that had been 
streaked with Staphylococcus aureus and were incubated 
in an incubator at 37°C for 24 hours. The inhibitory effect 
of each sample was evaluated by measuring the diameter 
of the clear area around the sample where bacteria growth 
was inhibited (known as the inhibition zone). The samples 
were then transferred to fresh bacteria-streaked agar plates to 
analyze the inhibitory effect provided by the remaining drug 
within the samples. Each test of antibacterial activity of the 
samples against Staphylococcus aureus was performed for 
4 consecutive days or until the samples had lost their antibac-
terial ability. The antibacterial experiments were performed 
in triplicate. All results are expressed as the mean ± standard 
deviation of the mean. A t-test was used to determine which 
differences between groups were significant. A P-value less 
than 0.05 was considered significant.
HDF growing on the PDGF- and RGDS-
conjugated ENSs
To investigate the behavior on bioactive molecule immobi-
lized ENSs, the cultivated HDF was seeded on the PDGF-BB- 
and RGDS-conjugated ENS and the control samples without 
conjugation. The conjugation method was the same as 
described in the previous section. Scaffolds were sterilized 
under ultraviolet light for 30 minutes and immersed in 70% 
ethanol for 30 minutes. After being cultured for 24 hours, 
HDFs cultured on various ENSs were fixed with 4 vol% 
paraformaldehyde in PBS for 30 minutes, and washed with 
PBS three times for 5 minutes each. After fixation, the cells 
were permeabilized by 0.1% Triton® X-100 (Dow Chemical 
Company, Midland, MI) in PBS for 10 minutes, and then the 
cells were rinsed in PBS three times. The cells were incubated 
in 10 µM phallacidin/1% (w/v) BSA solution for 20 minutes 
followed by rinsing in PBS three times. The cells were then 
incubated in 10 µM ToPro-3 for 20 minutes, followed by 
PBS washing three times. The ENSs were dried by air flow 
and mounted between cover slip and microscope slide and 
examined by CLSM.
Table 1 Sample names and specifications
Hybrid (PLLA/PLLA- 
b-PEG) ENS
Hybrid ENS functionalized   
with both rhodamine- 
BSA and FITC-BSA
Blank H0-1 H0-3
3% TCH H3-1 H3-3
Abbreviations: BSA, bovine serum albumin; ENS, electrospun nanofibrous scaffold; 
FITC, fluorescein isothiocyanate; PEG, poly(ethylene glycol); PLLA, poly(L-lactide); 
TCH, tetracycline hydrochloride.
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Results
Morphology and functionalization of the 
electrospun nanofibers
The blank PLLA-PEG-NH2/PLLA (hybrid) nanofibers 
(641 nm) and blank hybrid ENS functionalized with 
conjugation (608 nm) were uniform and smooth on the 
  surface, as shown in Figure 2A and B. Drug-loaded   nanofibers 
without (740 nm) and with conjugation (780 nm) are shown 
in Figure 2C and D. The size of the drug-loaded   nanofibers 
increased slightly, but the surfaces remained smooth with 
no visible drug crystals.
To test the validity of the immobilization method pre-
sented in Figure 1, NHS was coupled to the carboxyl groups 
of surface hydrolyzed ENS, resulting in the formation of an 
NHS ester, as shown in Figure 3A, with the amide I band at 
1646 cm−1. EGS was conjugated to the amino groups of water 
vapor-treated ENS to form an amide, which was present at 
1646 cm−1, as shown in Figure 3B.
SEM images of the hybrid scaffolds functionalized with 
two model BSA proteins are shown in Figure 2C. The BSA-
functionalized nanofibers appeared to be thicker than the 
original nanofibers. This increased thickness may have been 
caused by the swelling of the nanofibers after their reaction 
with the BSAs. Confocal microscopy was used to examine the 
nanofibers conjugated with two fluorescently labeled BSAs. 
Hybrid nanofibers functionalized with both FITC-BSA and 
rhodamine-BSA are shown in Figure 4A, B, and C. The green 
FITC image (Figure 4A), red rhodamine image   (Figure 4B), 
and a merged image (Figure 4C) show that the BSAs were 
present on the surface of the hybrid nanofibers. This result 
suggests that the two model proteins were immobilized on 
the surfaces of these nanofibers.
In vitro release of TCH from drug-loaded 
scaffolds
TCH release from ENSs was monitored by UV-Vis spec-
trometry at a wavelength of 366 nm to confirm that the drugs 
could be released in a controlled and sustained manner and to 
determine whether conjugation of BSA to the scaffold BSA 
influenced the release rate. The encapsulation rate of TCH 
was 70% for ENSs without BSA conjugation (H3-1) and 
30% for ENSs with two conjugated BSAs (H3-3) (Figure 5). 
TCH underwent a burst release from H3-1, with nearly 
70 µg of TCH being released during the first 24 hours. The 
drug was then released in a slower manner from the ENS 
during the next 100 hours. The cumulative drug release was 
85 µg. The profiles of TCH release from H3-3 are shown in 
Figure 5. In this case, TCH was sustainably slow released 
from H3-3 fibers over time, and no obvious burst release 
was observed in the whole incubation time span. There 
might be two major reasons for the lack of burst release and 
sustainable drug release. Firstly, the surface BSA coating on 
the fibers may contribute to this controlled release of drug 
from the fibers. The other reason is because the reactions in 
which the proteins were added were performed in aqueous 
solutions; thus, the burst release of TCH may already have 
occurred. Therefore, the BSA-conjugated samples had a 
lower cumulative TCH release (45 µg) compared with that 
of H3-1.
Antibiotic susceptibility test
The antibacterial capacity of TCH-loaded ENSs was evaluated 
using the microorganism susceptibility test. The effect of 
surface functionalized on the antibacterial capacity of drug-
loaded nanofibers was also determined. The diameter of the 
inhibition zone was used as a measure of the antimicrobial 
capacities of the nanofiber samples (Figure 6). The results 
are shown in Figures 6 and 7. The size of the inhibition 
zone decreased with time. The antibacterial capacities of the 
drug-loaded nanofibers lasted 6 days for the samples without 
conjugated BSA (H3-1) and only 3 days for the samples with 
two conjugated BSAs (H3-3). Thus, H3-1 (no conjugation) 
had a significantly higher (P , 0.05) antibiotic capability 
than H3-3. This difference may be a result of the aqueous 
environment used in the BSA functionalization, which may 
have led to drug loss. The hybrid samples underwent the 
BSA immobilization process twice, causing a larger amount 
of TCH loss. However, the samples still keep antibiotic 
capability, and this drug loss can be compensated for by the 
incorporation of a larger percentage of drug, which will be 
done in future studies.
Figure  2  Scanning  electron  microscopy  micrograph  of  (A)  H0-1,  (B)  H0-3, 
(C) H3-1, and (D) H3-3. Bar: 2 µm.
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Figure 3 FTIR-ATR spectra of ENSs conjugated with two model agents. (A) A hybrid ENS coupled with NHS by EDC. (B) An ENS coupled with EGS.
Abbreviations: EDC, 1-Ethyl-3-(3-dimethyl aminopropyl) carbodiimide hydrochloride; EGS, ethylene glycol-bis(succinimidyl succinate); ENS, electrospun nanofibrous 
scaffold; FTIR-ATR, Fourier transform infrared attenuated total reflectance; NHS, N-hydroxysuccinimide.
Cell adhesion and proliferation on 
nanofibrous scaffold
The HDFs cultivated on ENSs (with and without conjugation 
of PDGF-BB and RGDS) were immunostained with 
  fluorescent reagents and visualized by confocal microscopy, 
as shown in Figure 8. The cytoskeleton was stained as green 
color by phallacidin, and the nuclei were stained as far-red 
by ToPro-3 and changed to blue color by software (as shown 
in Figure 8).
Discussion
ENSs have been described as a promising multiscale bio-
mimetic matrix for tissue engineering. At the microscale 
level, nanofibers can: (1) mimic the interactions between 
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a ligand and a receptor, (2) be patterned to modulate cell 
differentiation, and (3) act as a nanomedicine that promotes 
tissue healing and protects the wound bed from bacterial 
invasion. At the mesoscale level, ENSs can: (1) act as a 
mechanical regulator that directs cell migration,   proliferation, 
and differentiation; (2) provide a framework for the regen-
eration of new tissues; (3) serve as a vehicle for cells and 
growth factors; (4) maintain the wound shape to minimize 
the deformation of the surrounding tissue; and (5) serve as 
a barrier to protect against infiltration of the surrounding 
tissue, which may impede the regeneration process. At 
the   macroscale level, ENSs can act as a tissue mimic with 
integrated multifunctionality to substitute for lost or diseased 
tissues.
The presence of multiple growth factors or regulators 
is a requirement during the tissue healing process, from 
a developmental biology perspective. For example, bone 
morphogenetic protein (BMP)-2 promotes bone reconstruc-
tion and aids in angiogenesis in the presence of vascular 
endothelial growth factor (VEGF). VEGF and insulin-like 
growth factor (IGF)-1 can be delivered together to promote 
muscle regeneration after ischemic muscle injury.25 VEGF 
administration followed by PDGF-BB addition has been used 
to improve vascularization.26 Recently, a technology was 
developed to deliver multiple growth factors by sacrificing 
microsphere-loaded nanofibers (phase I), resulting in the 
microspheres being entrapped within the nanofiber (phase II) 
scaffolds.27 However, most existing scaffolds for implanta-
tion carry no more than two types of therapeutic agents, 
which may hinder the efficacy of scaffold transplantation.
In this study a multifunctional ENS was constructed 
using PLLA/PLLA-PEG-NH2 that can carry up to three 
bioactive molecules. Antibiotic-loaded nanofibers were 
first fabricated with a core-sheath structure using an emul-
sion electrospinning method. Adhering to the principle 
of minimal system energy, hydrophilic NH2 groups were 
designed to be projected into a hydrophilic environment 
by exposing the nanofibers to water vapor. The model pro-
tein rhodamine-BSA was conjugated to the NH2 groups. 
Figure 4 Confocal images of PLLA/PLLA-PEG-NH2 nanofibers functionalized with both FITC-BSA and rhodamine-BSA. (A) Image showing FITC-BSA, (B) image showing 
rhodamine-BSA, and (C) merged A and B. Bar: 20 µm.
Abbreviations: BSA, bovine serum albumin; FITC, fluorescein isothiocyanate; PEG, poly(ethylene glycol); PLLA, poly(L-lactide).
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Figure 5 Controlled release from TCH-loaded ENSs with (H3-3) and without 
(H3-1) conjugated BSA. All samples were 3% TCH-loaded ENSs (n = 3).
Abbreviations: BSA, bovine serum albumin; ENS, electrospun nanofibrous scaffold; 
TCH, tetracycline hydrochloride.
Figure 6 Antibacterial tests of H3-1 and H3-3. (A) Day 1 H3-3 (left) and H3-1 
(right); (B) day 2 H3-3 (left) and H3-1 (right); (C) day 3 H3-3 (left) and H3-1 (right); 
and (D) day 4 H3-1 (H3-3 was discarded). Bar: 5 mm.
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Next, hydrolysis of the nanofiber surface was conducted 
to activate the carboxylic groups, to which the second 
model protein, FITC-BSA, was conjugated. The covalent 
conjugation allows therapeutic agents a more sustainable 
and controllable release than physical loading.28,29 Several 
applications for the ENS system can be found in the heal-
ing process of tissues and organs. This system is suitable 
for skin repair, where antibacterial properties are crucial 
for proper healing, and the release of growth factors (ie, 
PDGF-BB and epidermal growth factor [EGF]) is impor-
tant for maintaining regenerative capabilities. The system 
can also be adapted to accelerate bone healing when bones 
have critical defects by releasing VEGF to promote vascu-
larization, BMP-2 to promote osteogenesis, and BMP-7 to 
promote both chondroblastic and osteoblastic differentiation. 
Alternatively, the triple-functionalized scaffold system can 
be engineered to promote muscle regeneration by delivering 
VEGF and PDGF-BB to promote angiogenesis and IGF-1 to 
promote muscle regeneration. Biomaterial surfaces can have 
profound regulatory effects on stem cell differentiation.30,31 
For example, a fibronectin-coated surface has been shown to 
modulate integrin adhesion receptor binding.32 Even hydro-
philicity is able to control the growth of a stem cell colony.31 
ENSs can be used to investigate tissue regeneration and 
stem cell modulation through the surface functionalization 
of different epitopes (eg, Arg-Gly-Asp, Pro-His-Ser-Arg-
Asn) along with synergic growth factors.
To present the efficacy of the cell growth on biocon-
jugated ENSs, PDGF-BB and RGDS were sequentially 
conjugated to ENSs. HDFs were seeded on scaffolds with 
and without conjugation. Cell adhesion and morphology 
are known as indicators for cell growth. RGD peptide can 
improve cell adhesion by recognizing the specific adhesion 
receptors of cell membranes, and PGF-BB has been veri-
fied in clinics to promote wound healing. When the cells 
seeded on the PDGF-BB- and RGDS-conjugated ENSs 
for 24 hours, HDFs extended along polymer fibers and 
increased cell adhesion area, resulting in cell spreading 
on the polymer fibrous scaffold. In comparison, the cells 
on without conjugation ENS for 24 hours migrated and 
extended only a little bit with a round shape on the scaffold. 
  Figure 8A and B clearly shows the difference between 
scaffolds with and without conjugation. Furthermore, the 
therapeutic agents remain active after conjugation from 
Figure 8.
Although the results and methods of this study are promis-
ing, some concerns remain. First, ENSs were fabricated using 
a PLLA/PLLA-b-PEG-NH2 hybrid. The molecular weight of 
PLLA-b-PEG-NH2 is about 20 kD, which is not appropri-
ate for electrospun nanofibers. The PLLA hybrid and the 
copolymer increase the uniformity of the electrospun fibers, 
while decreasing the hydrophilicity of the ENS. Second, it 
is not clear how the ratio of PLLA to copolymer influences 
protein immobilization or drug loading. It is important to 
identify the optimal ratio to achieve the ultimate goal of 
regeneration. Third, the drug loaded in the study had a low 
molecular weight. The addition of high molecular weight 
drugs, such as growth factors, to the nanofiber core-shell 
structure requires different electrospin parameters. Fourth, 
protein conjugation leads to a decreasing efficacy of drug 
release from the ENS. Finally, further cell biological works 
should be conducted to verify the efficacy in tissue engineer-
ing by providing more profound results. These concerns will 
be important to consider in further development of ENSs 
for their intended applications and will be addressed in the 
authors’ future work.
Figure 8 Immunofluorescence staining of human dermal fibroblasts on ENSs of   
(A) PDGF and RGDS conjugated and (B) blank. Images were recorded by a confocal 
microscope. The same magnification was used for both pictures. Bar: 100 µm.
Abbreviations:  ENS,  electrospun  nanofibrous  scaffold;  PDGF,  platelet-derived 
growth factor; RGDS, Arg-Gly-Asp-Ser.
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Figure 7 Antibacterial tests of H3-1 and H3-3. 
Note: *P , 0.05 based on the statistical analysis for the inhibition zone tests 
comparing H3-1 and H3-3 at days 1, 2, 3, and 4.
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Conclusion
In this work, multifunctional ENSs were developed that 
incorporated the antibacterial agent TCH and were surface 
functionalized with two different bioactive molecules. TCH 
was loaded into PLLA/PLLA-PEG-NH2 nanofibers by 
emulsion electrospinning and was released from the nanofi-
bers in a sustained manner. FTIR-ATR spectra and CLSM 
images showed that two fluorescently labeled BSAs could 
be successfully immobilized on the surface of the modified 
drug-loaded nanofibers, and the resulting nanofibrous mat 
still retained its antibacterial properties. This novel material 
may have potential applications in wound care and tissue 
engineering, which require multifunctional materials that 
have antimicrobial properties and also promote wound heal-
ing or tissue regeneration.
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Figure S1 Nuclear magnetic resonance spectrum of the PLLA-b-PEG-NH2 block copolymer.
Notes: The peak at δ5.1 corresponds to the CH groups in the PLA blocks; the peak at δ3.6 corresponds to the CH2 groups in the PEG blocks; and the peak at δ1.6 
corresponds to the CH3 groups in the PLA block.
Abbreviations: PEG, poly(ethylene glycol); PLLA, poly(L-lactide).
Figure S2 Confocal image of the drug-laden nanofiber with FITC-BSA conjugation only. Bar: 5 µm.
Abbreviations: BSA, bovine serum albumin; FITC, fluorescein isothiocyanate.
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